A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking to license the product or to sell the program outright. Read the company's press release. … [Read more...] about Intranasal insulin company CPEX acquired
News
Inspire’s CF drug fails Phase 3 trial
The results from Inspire Pharmaceuticals' second Phase 3 trial of denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis show that the drug failed to meet its primary endpoint, change in FEV from baseline. Denufosol is an ion channel regulator. A previous Phase 3 trial had produced significant change in FEV from baseline, and the company says … [Read more...] about Inspire’s CF drug fails Phase 3 trial
Mannkind announces delay on Afrezza decision
According to Mannkind Corporation, the FDA has informed the company that it will need another four weeks or so before it issues a decision on the NDA for Afrezza inhaled insulin. The original action date was to be December 29, 2010. The FDA issued a complete response letter for the product in March and requested additional data. Read the company's press release. … [Read more...] about Mannkind announces delay on Afrezza decision
Procept and Ingeniatrics to team up on new spray dryer system
Belgian pharma equipment manufacturer Procept and Spanish tech company Ingeniatrics Tecnologías have signed an agreement to develop a new spray drying system based on Ingeniatrics' Flow Focusing technology, which is a "microfluidic technology capable of monodispersed droplet formation and manipulation, based on the production of capillary microjets that are … [Read more...] about Procept and Ingeniatrics to team up on new spray dryer system
Strativa president John A. MacPhee resigns
Patrick G. LePore, President, CEO, and Chair of Par Pharmaceuticals will temporarily take over the reins at the company's subsidiary Strativa Pharmaceuticals after Strativa's President John A. MacPhee resigned. MacPhee was also Executive VP of Par. Strativa's products include Nascobal cyanocobalamin nasal spray. Read the company's press release. … [Read more...] about Strativa president John A. MacPhee resigns
Forest regains European rights to Colobreathe
Forest Laboratories has reached an agreement with Gruenenthal to reacquire the European rights to the Colobreathe colistin DPI for the treatment of P. aeruginosa infections in cystic fibrosis patients.The EMA is currently reviewing Forest's marketing application for the product. Read the company's press release. … [Read more...] about Forest regains European rights to Colobreathe
MAP completes final Levadex trial
According to MAP Pharmaceuticals, it has completed a year-long open label safety trial of its Levadex inhaled dihydroergotamine, the final step in its development program for the product. More than 250 patients completed the 12-month study. The company plans to submit an NDA for Levadex in the first half of 2011. Read the company's press release. … [Read more...] about MAP completes final Levadex trial
Generex gets another Canadian patent for aerosol formulations
Generex has received a patent from the Canadian Intellectual Property Office for its aerosol drug delivery platform, its 162nd patent for the technology. Although the company announcement emphasizes its buccal delivery platform, the patent is titled Aerosol Formulations for Buccal and Pulmonary Application. Generex's Oral-lyn buccal insulin spray is delivered via … [Read more...] about Generex gets another Canadian patent for aerosol formulations
Westech announces launch of new Novi inhaler testing system
Westech Scientific Instruments is now offering the Vertus MDI Actuation Station, a "shake and fire" system for inhaler testing from automation firm Novi. The system offers programmable agitation, encrypted data transfer, and the ability to connect to measurement devices including the ACI, NGI, or DUSA. Read the Westech product release. … [Read more...] about Westech announces launch of new Novi inhaler testing system
Cypress Bioscience to merge with Ramius and Royalty Pharma
The board of Cypress Bioscience has agreed to be acquired by investment companies Ramius and Royalty Pharma for $6.50 per share, a total value of more than $250 million. In August 2010, Cypress acquired two OINDPs: Staccato nicotine for smoking cessation from Alexza and intranasal carbetocin for the treatment of autism symptoms from Marina Biotech (formerly Nastech). … [Read more...] about Cypress Bioscience to merge with Ramius and Royalty Pharma